Whalesbook
Sun Pharma ka stock kyon gira?
Sun Pharma ne March quarter mein achha profit toh dikhaya, lekin margin kam hone aur US market mein sales girne ki wajah se stock price mein kami aayi.
Revenue badha, par Margin kaise kam hua?
March 2026 quarter ke liye, Sun Pharma ka consolidated revenue 12.8% badh kar ₹14,612 crore ho gaya. Lekin, EBITDA sirf 6.4% badh kar ₹3,954 crore tak pahuncha. Is wajah se EBITDA margin 27.06% ho gaya, jo pichhle saal isi time 28.68% tha. Yeh 162 basis points ki kami bata rahi hai ki revenue generate karne ka kharcha badh gaya hai.
US Market mein slowdown aur sales ka scene
India mein formulations sales 14.8% aur innovative medicines 20.1% badhi. Lekin, US formulations business ki sales 1.1% gir gayi, jo $459 million rahi. US market mein yeh slowdown, jo Sun Pharma ke liye kaafi important hai, margin compression ki chinta ko aur badha raha hai. Overall sales 13.6% badh kar ₹14,559.8 crore hui, jismein domestic sales aur specialized products ka bada role raha, lekin US ki performance ne investors ka mood kharab kiya. Sun Pharma ne India mein market share 0.3 percentage points badhaya hai fiscal year 2026 ke liye, jo Ranbaxy acquisition ke baad sabse bada gain hai, par isse negative factors ko poori tarah cover nahi kiya ja saka.
Valuation aur acquisition ki chinta
Sun Pharma ka Price-to-Earnings (P/E) ratio lagbhag 41.03 hai, jo pharmaceutical sector ke average 38.9 se zyada hai. Competitors jaise Zydus Lifesciences ka P/E 30x aur Dr. Reddy's Laboratories ka 26.50x hai. Itna zyada valuation ka matlab hai ki investors bahut zyada future growth expect kar rahe hain, jo ab margin pressure ke karan mushkil lag raha hai. Pichhle records dekhein toh Sun Pharma ka stock margin concerns par pehle bhi gir chuka hai; jaise May 2024 mein yeh 4% se zyada gira tha jab guidance ne FY25 ke liye margin pressure ka ishara diya tha. Haal hi mein, April 2026 mein Organon ko $11.75 billion mein acquire karne ka deal hua hai, jisse company apni global presence aur innovative medicines portfolio ko boost karna chahti hai. Lekin, Organon jiske paas $8.6 billion ka debt hai aur jise lagbhag 6.2 times EBITDA par value kiya gaya hai, use integrate karna ek bada risk hai.
Integration Risks aur Margin Pressure
Organon acquisition, chahe strategic taur par sahi ho, lekin integration risks aur Sun Pharma par financial leverage ko badha degi. Organon ka substantial debt Sun Pharma ke overall debt ko badhayega. Acquisition ki valuation 6.2 times EBITDA par, jo aajkal ke pharmaceutical deals ke hisab se kam hai, yeh Organon ke slow growth aur debt load ke baare mein chinta dikha sakti hai. Iske alawa, Sun Pharma ke manufacturing facilities mein pehle ki regulatory issues, jaise Halol plant ki Halol plant ka status jo US sales ko affect karta hai, woh ongoing risks hain jo combined entity ki performance aur synergy ko rok sakte hain. Lagatar margin pressure yeh bata raha hai ki cost efficiencies revenue growth ke saath kadam nahi mila paa rahi hain, aur Organon ko integrate karne se yeh challenge aur badh sakta hai.
Analyst Kya Keh Rahe Hain?
Analysts generally positive hain, consensus 'Buy' rating ke saath aur average 12-month price target ₹2,048.79 ke aas-paas hai. Yeh positive outlook Organon acquisition ke successful integration aur innovative medicines aur domestic market mein continued growth par depend karta hai. Lekin, agar margins mein aur kami aati hai ya Organon deal se fayda milne mein deri hoti hai, toh yeh projections affect ho sakti hain.